title: An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital.
abstract: OBJECTIVE
  To validate a high performance liquid chromatography (HPLC) method for serum teicoplanin measurement and use the method for clinical monitoring of teicoplanin levels to analyze the clinical application of teicoplanin.
  
  
  METHODS
  55 patient profiles were collected and analyzed for the clinical teicoplanin application. 10 critically ill patients of the 55 cases were monitored for teicoplanin trough concentration using the HPLC method.
  
  
  RESULTS
  The modified HPLC method exhibited excellent linearity, with correlation coefficient r = 0.9995. The intra-day and inter-day coefficients of variation were less than 10%. The lower limit of detection of teicoplanin was 5.63 mg/l. The recovery of teicoplanin was above 90%. Of the 55 patients in this study, there were 42 patients without load-dosing. There were only 29 patients treated with teicoplanin documented Gram-positive infections by etiological diagnoses. In the 10 patients with teicoplanin serum trough concentration monitoring, all cases received a loading dose of 400 mg every 12 h for 3 doses, and the mean trough concentration of teicoplanin was 10.82 ± 4.51 mg/l. The mean trough levels were 13.04 ± 6.23 mg/l in 4 patients with microbiological eradication and improvement of symptoms of diseases and 9.34 ± 2.61 mg/l in 6 patients with persistence of previous clinical infectious symptoms, respectively.
  
  
  CONCLUSIONS
  The modified HPLC method is robust, highly reproducible and suited to monitor the concentration of teicoplanin. In critically ill Chinese patients, we should consider more appropriate loading doses and evaluate the relationship between teicoplanin trough concentration and the efficacy using microbiological and clinical parameters.
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital, Medical College, Xi'an JiaoTong University, Xi'an, China. dongyalin@medmail.com.cn
authors.forename: Y-L
authors.initials: YL
authors.lastname: Dong
authors.forename: H-Y
authors.initials: HY
authors.lastname: Dong
authors.forename: S-S
authors.initials: SS
authors.lastname: Hu
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: Y-X
authors.initials: YX
authors.lastname: Wei
authors.forename: M-Y
authors.initials: MY
authors.lastname: Wang
authors.forename: W-H
authors.initials: WH
authors.lastname: Dong
authors.forename: H-P
authors.initials: HP
authors.lastname: Yao
authors.forename: H-S
authors.initials: HS
authors.lastname: You
authors.forename: J-F
authors.initials: JF
authors.lastname: Xing
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016903:Drug Monitoring; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D017334:Teicoplanin / Q000097:blood*
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin